Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap
Massachusetts General Hospital · Institute for Biodiversity · +24 more institutions
Abstract
Candida parapsilosis is one of the most commen causes of life-threatening candidaemia, particularly in premature neonates, individuals with cancer of the haematopoietic system, and recipients of organ transplants. Historically, drug-susceptible strains have been linked to clonal outbreaks. However, worldwide studies started since 2018 have reported severe outbreaks among adults caused by fluconazole-resistant strains. Outbreaks caused by fluconazole-resistant strains are associated with high mortality rates and can persist despite strict infection control strategies. The emergence of resistance threatens the efficacy of azoles, which is the most widely used class of antifungals and the only available oral…
Citation impact
- FWCI
- 41.83
- Percentile
- 100%
- References
- 73
Authors
15- FDFarnaz Daneshnia
Massachusetts General Hospital, Institute for Biodiversity, University of Amsterdam
- JNJoão Nóbrega de Almeida
Hospital Israelita Albert Einstein, Hospital São Paulo, Universidade Federal de São Paulo
- MİMacit İlkit
Cukurova University
- LLLisa Lombardi
University College Dublin
- AMAustin M. Perry
University of California, Merced
Topics & keywords
- Fluconazole
- Candida parapsilosis
- Outbreak
- Echinocandin
- Azole
- Biology
- Drug resistance
- Intensive care medicine
- Good health and well-being
Funding
- GAGordon and Betty Moore FoundationAward: GBMF9742
- GSGilead Sciences
- MSMemorial Sloan-Kettering Cancer CenterAward: CA008748
- “C“la Caixa” FoundationAward: LCF/PR/HR21/00737
- ECEuropean CommissionAwards: ERC-2016-724173, 724173
- MDMinisterio de Ciencia e InnovaciónAward: PID2021-126067NB-I00
- APAstellas Pharma
- FBFundación Bancaria Caixa d'Estalvis i Pensions de Barcelona
- NINational Institutes of HealthAwards: P30 CA008748, R37 AI093808, R01 AI139632, R35 GM124594, R21 AI156157
- HEHORIZON EUROPE Framework Programme
- ADAgència de Gestió d'Ajuts Universitaris i de RecercaAward: SGR423
- IDInstituto de Salud Carlos IIIAwards: CIBERINFEC CB21/13/00061, IMP/00019, CIBERINFEC CB21/13/00061-ISCIII-SGEFI/ERDF
- EREuropean Regional Development FundAward: IMP/00019
- NKNational Key Research and Development Program of ChinaAwards: 2021YFA0911300, P30 CA008748